Moreover, TAMs express Fc receptors that inhibit the binding of anti-PD1 antibodies to T cells, thereby preventing the suppression of PD1/PD-L1 signaling, leading to resistance to anti-PD1 therapy using in vivo tumor models [172]. The gene discussed is CD274; the disease is neoplasm.